Medical AI Alliance
← Company Index
Pharma & CDMOKOSDAQ 08690021 approvals19 trials

Medy-Tox Inc.

Official website

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

As of 2026-10-10, Medy-Tox Inc. has 11 Korean MFDS device approvals, 10 Korean MFDS drug approvals, 48 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Medy-Tox was founded on May 2, 2000 and listed on KOSDAQ on January 16, 2009, engaging in research, manufacturing, and sales of Clostridium botulinum toxin type A biopharmaceuticals. Its flagship product Meditoxin(R) (Neuronox(R)) is joined by Innotox(R), the world's first liquid-type botulinum toxin type A product, Coretox, and the Neuramis(R) HA filler series. In its 26th fiscal year, consolidated revenue was about KRW 247.3 billion, with Meditoxin and other core products accounting for approximately 87% and medical devices and services about 13%, while the company exports Neuronox(R) and the Neuramis(R) series to around 30 countries from its Ochang and Osong, Cheongju production facilities.

Products & technology

  • Meditoxin® / Neuronox®Botulinum toxin type A pharmaceutical (flagship product)
  • Innotox®World's first liquid-type botulinum toxin type A pharmaceutical
  • CoretoxBotulinum toxin pharmaceutical using non-animal excipients (L-methionine, polysorbate)
  • Neuramis® seriesExport product (aesthetics market, HA filler line)

Regulatory approvals

data.go.kr

10 Korean MFDS drug approvals · 2006–2025 / 11 Korean MFDS device approvals · 2011–2019

  • MFDS drugNUVIJU Inj.(Cholic acid)2025-09-19
    Drug · Prescription · Approval202502484
  • MFDSGraft/prosthesis, biomaterial2019-08-26
    Product approval · Class 4제허 19-561 호
  • MFDSDressing, adhesion barrier2019-07-31
    Product approval · Class 3제허 19-512 호
  • MFDS drugMEDYTOX ADETRI INJ2017-09-08
    Drug · Prescription · Notification201707024
  • MFDS drugMEDYTOX HYALASE INJ2017-09-07
    Drug · Prescription · Notification201706998
  • MFDS drugMEDYTOX GLUTA INJ2017-09-07
    Drug · Prescription · Notification201707005
  • MFDS drugCoretox Inj.2016-06-24
    Drug · Prescription · Approval201603891
  • MFDSGraft/prosthesis, biomaterial2014-12-09
    Product approval · Class 4제허 14-2923 호
  • MFDS drugInnotox Inj.2013-12-11
    Drug · Prescription · Approval201310633
  • MFDS drugMeditoxin Inj. 150U2013-10-15
    Drug · Prescription · Approval201309732
  • MFDSGraft/prosthesis, biomaterial2013-05-16
    Product approval · Class 4제허 13-871 호
  • MFDSGraft/prosthesis, biomaterial2012-11-21
    Product approval · Class 4제허 12-1480 호
Show 9 more
  • MFDSGraft/prosthesis, biomaterialRevoked2012-10-29
    Product approval · Class 4제허 12-1370 호
  • MFDSGraft/prosthesis, biomaterial2012-10-29
    Product approval · Class 4제허 12-1369 호
  • MFDSGraft/prosthesis, biomaterial2012-10-29
    Product approval · Class 4제허 12-1368 호
  • MFDSGraft/prosthesis, biomaterial2012-02-22
    Product approval · Class 4제허 12-216 호
  • MFDSGraft/prosthesis, biomaterial2011-11-16
    Product approval · Class 4제허 11-1262 호
  • MFDSGraft/prosthesis, biomaterial2011-10-10
    Product approval · Class 4제허 11-1112 호
  • MFDS drugMEDITOXIN Inj.2010-02-24
    Drug · Prescription · Approval201001655
  • MFDS drugMeditoxin Inj. 200U2009-03-31
    Drug · Prescription · Approval200902348
  • MFDS drugMeditoxin Inj.2006-03-16
    Drug · Prescription · Approval200600841

Clinical trials

data.go.kr

19 MFDS clinical trial authorisations · 2012–2021 (Phase 1 8 · Phase 3 7 · Phase 2 4)

  • Phase 3MT9212021-06-16

    10 trial sites

  • Phase 2MT9212019-07-25

    12 trial sites

  • Phase 3메디톡신주(클로스트리디움 보툴리눔 독소 A형)2019-04-17

    7 trial sites

  • Phase 1MT9212018-06-22

    1 trial site

  • Phase 3메디톡신주(클로스트리디움 보툴리눔 독소 A형)2018-05-11

    13 trial sites

  • Phase 1MBA-P012018-03-30

    1 trial site

  • Phase 3메디톡신주(클로스트리디움 보툴리눔 독소 A형)2018-02-05

    4 trial sites

  • Phase 1메디톡신주(클로스트리디움 보툴리눔 독소 A형)2018-01-24

    1 trial site

  • Phase 2메디톡신주(클로스트리디움 보툴리눔 독소 A형)2017-12-28

    2 trial sites

  • Phase 1메디톡신주(클로스트리디움 보툴리눔 독소 A형)2017-10-31

    4 trial sites

  • Phase 1메디톡신주(클로스트리디움 보툴리눔 독소 A형)2017-08-18

    1 trial site

  • Phase 1메디톡신주(클로스트리디움 보툴리눔 독소 A형)2017-07-10

    3 trial sites

Show 7 more
  • Phase 1메디톡신주(클로스트리디움 보툴리눔 독소 A형)2017-05-02

    6 trial sites

  • Phase 3메디톡신주(클로스트리디움 보툴리눔 독소 A형)2017-04-03

    3 trial sites

  • Phase 2메디톡신주(클로스트리디움 보툴리눔 독소 A형)2013-12-26

    2 trial sites

  • Phase 3메디톡신주(클로스트리디움 보툴리눔 독소 A형)2013-09-26

    1 trial site

  • Phase 2메디톡신주(클로스트리디움 보툴리눔 독소 A형)2012-08-03

    4 trial sites

  • Phase 1메디톡신주(클로스트리디움 보툴리눔 독소 A형)2012-07-24

    1 trial site

  • Phase 3메디톡신주(클로스트리디움 보툴리눔 독소 A형)2012-07-11

    3 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched
Show 39 more trials

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 38 more publications

Patents

KIPRIS · applicant-matched
Show 129 more patents

AI reads

MAA server logs · IP-verified
267
Times AI engines pulled Medy-Tox Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

3
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

264
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

16
live 2
Last 7 days
209
live 3
Last 30 days
267
live 3
All time
  • OpenAIChatGPT-Userlive3
  • OpenAIOAI-SearchBot213
  • GoogleGoogleOther38
  • PerplexityPerplexityBot11
  • AnthropicClaudeBot2

Measured since Aug 26, 2026 · 4 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Medy-Tox Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · R&D. Send us materials and we will add them

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

BioPlus Co., Ltd2 shared

Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.

Chabiotech Co.,Ltd.2 shared

Cord blood storage and cell therapy company that has expanded into global CDMO manufacturing and overseas medical network services.

JETEMA Co.,Ltd.2 shared

Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.

BNC KOREA, Inc.2 shared

Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.

DongKookPharmaceuticalCo.,Ltd.2 shared

KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.

HANS BIOMED CORPORATION1 shared

KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.

BASKHANBIOPharma Inc.1 shared

Founded 1986, KONEX-listed since 2022, BASKHANBIOPharma makes drugs and medical devices for use before and after surgery.

DONGWHA PHARM.CO.,LTD1 shared

Dongwha Pharm, founded in 1897 and KOSPI-listed in 1976, is a diversified company centered on pharmaceuticals.

BIOBIJOU Co., Ltd.1 shared

KOSDAQ-listed aesthetics exporter behind HA skin booster CANDOLOV SERUM and filler brands COLENA and CANDORLOV.

Daehan Nupharm Co.,Ltd.1 shared

KOSDAQ-listed pharmaceutical company producing a diverse, low-volume portfolio of metabolic disease drugs, wellness injections, and veterinary medicines.

Hironic Co.,Ltd1 shared

KOSDAQ-listed medical device company producing HIFU devices DOUBLO/V-RO and the Synerjet non-invasive drug delivery system for aesthetic dermatology.

METABIOMED.CO.,LTD1 shared

KOSDAQ-listed medical device company manufacturing synthetic bioresorbable suture yarn and dental root canal filling materials.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition